Elevated levels of T-cell immune response cDNA 7 in patients with immune thrombocytopenia

Zhu, Feng; Qiao, Jianlin; Wu, Qingyun; Cao, Jiang; Zeng, Lingyu; Li, Zhenyu; Xu, Kailin

doi:10.1179/1607845414y.0000000156

Cited by 6 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TIRC7 is expressed in immune organs, such as the spleen, and in T and B lymphocytes, playing a vital role in kidney and cardiac transplantation, as well as in collagen-induced arthritis (8,9,11,12). Our previous study revealed that TIRC7 may be involved in the pathogenesis of immune thrombocytopenia (ITP) and may serve as an indicator for evaluating the efficacy of ITP treatment (13). In addition, TIRC7 plays a central role in allograft rejection and inflammation (14).…”

Section: Introductionmentioning

confidence: 99%

Role of T cell immune response cDNA 7 on the pathology of acute graft‑versus‑host disease

Zhu

Fan

et al. 2020

Oncol Lett

Self Cite

View full text Add to dashboard Cite

Activation of T lymphocytes is the initiating factor of the occurrence of acute graft-versus-host disease (aGVHD), and cytotoxic T lymphocyte antigen-4 (CTLA-4) is the inhibitory receptor for activating T cells. T cell immune response cDNA 7 (TIRC7) is considered an upstream regulator of CTLA-4; however, little is understood regarding the effects of TIRC7 on the regulation of CTLA-4 in aGVHD. The purpose of the present study was to evaluate the regulatory effects of TIRC7 on aGVHD, mainly in the pathology. Recipient mice were exposed to a preconditioning dose of 7.5 Gy irradiation on the day of the transplantation and were divided into the following groups: Blank control group, bone marrow transplantation control group, total body irradiation group, mild-moderate aGVHD group and severe aGVHD group. According to the different administration of CTLA-4 and TIRC7 monoclonal antibodies, the mild-moderate and severe aGVHD groups were randomly divided into the hematopoietic stem cell transplantation (HSCT) and HSCT + CTLA-4/TIRC7 groups. Recipient mice were sacrificed at different time points post-HSCT for histopathological analysis by hematoxylin and eosin staining. Compared with the control and other experimental groups, the mice in the combined CTLA-4 and TIRC7 group exhibited ameliorated pathological injury, and lower pathology scores of the liver, lung and intestine. These data revealed that intraperitoneal injection of anti-TIRC7 and/or anti-CTLA-4 monoclonal antibody into mice could effectively alleviate the severity of aGVHD.

show abstract

Section: Introductionmentioning

confidence: 99%

Role of T cell immune response cDNA 7 on the pathology of acute graft‑versus‑host disease

Zhu

Fan

et al. 2020

Oncol Lett

Self Cite

View full text Add to dashboard Cite

show abstract

“…Meanwhile, some studies have also documented the importance of TIRC7 on some autoimmune diseases [16]; nevertheless, there were few relevant reports of TIRC7 in hematological diseases. We have previously documented that TIRC7 might be associated with the pathogenesis of immune thrombocytopenia and TIRC7 levels could be used as an indicator to evaluate patients' response to high-dose dexamethasone treatment [17]. We also showed that TIRC7 levels in patients with I-II acute graft-versus-host disease (aGVHD) were lower than that with III-IV aGVHD before or after treatment and its level in aGVHD might reflect the treatment efficacy [18].…”

Section: Introductionmentioning

confidence: 82%

Antithymocyte globulin combined with cyclosporine A down-regulates T helper 1 cells by modulating T cell immune response cDNA 7 in aplastic anemia

Zhu

Qiao

et al. 2015

Med Oncol

Self Cite

View full text Add to dashboard Cite

Antithymocyte globulin (ATG) combined with cyclosporine A (CsA) has been widely used as a standard regimen in the treatment of aplastic anemia (AA), especially in severe aplastic anemia (SAA). Abnormally activated T cells might be the immune pathogenesis of AA. T cell immune response cDNA 7 (TIRC7) has been demonstrated its essential role in T cell activation; however, little is known about the role of TIRC7 in AA. In this study, we documented that TIRC7 levels in CsA group were higher than that in ATG + CsA (AC) group only in the follow-up phase (P < 0.05; P < 0.05); nevertheless, TIRC7 levels in SAA group were elevated than non severe aplastic anemia group not only in the treatment phase (P < 0.05; P < 0.05) but also in the follow-up phase (P < 0.05; P < 0.01). The trend of changes of T helper (Th) 1, Th17 and Th22 levels before and after treatment was similar to the changes of TIRC7 levels in either AC group or CsA group. Thus, TIRC7 might be involved in the pathogenesis of AA and AC might down-regulate Th1 cells by modulating the expression of TIRC7 in AA.

show abstract

“…RT-qPCR to measure TIRC7 and CTLA-4. RT-qPCR analysis was performed as previously described (12). RNA was extracted from the peripheral blood of patients using Ficoll-Paque Plus (Sinopharm Chemical Reagent Co., Ltd.) and reverse transcribed to cDNA using a PrimeScript RT kit (Takara Bio, Inc.) according to the manufacturer's protocols.…”

Section: Construction Of Pgpu6-shtirc7 and Flag-ctla-4mentioning

confidence: 99%

TIRC7 inhibits Th1�cells by upregulating the expression of CTLA‑4 and STAT3 in mice with acute graft‑versus‑host disease

et al. 2020

Self Cite

View full text Add to dashboard Cite

In a previous study, it was demonstrated that T-cell immune response cDNA 7 (TIRC7) levels reflect the efficacy of treatment of patients with acute graft-versus-host disease (GVHD). However, the pathogenesis of TIRC7 in acute GVHD remains poorly understood. Lymphocytes from patients with acute GVHD were selected as targeT cells, and the effects of TIRC7 on cytotoxic T lymphocyte antigen-4 (CTLA-4), T cell activation and cytokine secretion were observed by electroporation. A mouse model of acute GVHD was established; anti-TIRC7 and anti-CTLA-4 monoclonal antibodies were intraperitoneally injected into recipient mice. Then, the effects of TIRC7 and CTLA-4 on T cell activation and acute GVHD were monitored. After TIRC7 expression was downregulated, CTLA-4 levels were decreased and STAT3 phosphorylation was reduced; conversely, the activation capacity of T lymphocytes was elevated, and the secretion of interferon-γ and other cytokines was increased. The mice in the TIRC7 + CTLA-4 co-administration group exhibited the lowest acute GVHD scores, with the longest average survival time and shortest recovery time of hematopoietic reconstitution. In conclusion, the results indicated that TIRC7 may positively regulate the function of CTLA-4 and inhibit T cell activation, thus suppressing the development and progression of acute GVHD.

show abstract

Elevated levels of T-cell immune response cDNA 7 in patients with immune thrombocytopenia

Abstract: TIRC7 might be associated with the pathogenesis of ITP, and TIRC7 levels could be used as an indicator to evaluate patients' response to HD-DXM treatment.

Cited by 6 publications

References 25 publications

Role of T cell immune response cDNA 7 on the pathology of acute graft‑versus‑host disease

Role of T cell immune response cDNA 7 on the pathology of acute graft‑versus‑host disease

Antithymocyte globulin combined with cyclosporine A down-regulates T helper 1 cells by modulating T cell immune response cDNA 7 in aplastic anemia

TIRC7 inhibits Th1�cells by upregulating the expression of CTLA‑4 and STAT3 in mice with acute graft‑versus‑host disease

Contact Info

Product

Resources

About